Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.63 |
| ▸ | ERBB2 | P04626 | 16/20 | 0.63 |
| ▸ | IGF1R | P08069 | 16/20 | 0.63 |
| ▸ | ERBB3 | P21860 | 16/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 16/20 | 0.63 |
| ▸ | LCK | P06239 | 4/20 | 0.59 |
| ▸ | SRC | P12931 | 4/20 | 0.59 |
| ▸ | TEK | Q02763 | 4/20 | 0.59 |
| ▸ | KDR | P35968 | 3/20 | 0.59 |
| ▸ | BTK | Q06187 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4827462 | 0.88 | EGFR (0.82) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6433960 | 0.88 | EGFR (0.82) | EGFRERBB2IGF1RERBB3ERBB4 | |
| Ammonia Solution, Strong SCHEMBL4828005 | 0.83 | EGFR (0.53) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6435385 | 0.78 | EGFR (0.85) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6435381 | 0.78 | EGFR (0.85) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4818337 | 0.78 | LCK (0.77) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL4818329 | 0.78 | LCK (0.77) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL5822885 | 0.78 | LCK (0.77) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL6433597 | 0.78 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 | |
| SCHEMBL5801190 | 0.78 | EGFR (1.00) | EGFRERBB2IGF1RERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | EGFR 1992/4885ERBB2 682/4885IGF1R 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.